Abstract
Prostate-specific membrane antigen (PSMA) expression has been observed in the neovasculature of various malignancies. We present a case of metastatic renal cell carcinoma (RCC) with comparative 18F-FDG PET/CT and 68Ga-PSMA-11 imaging in which FDG PET/CT failed to detect metastatic thyroid disease and showed less 18F-FDG–concentrating lesions at other sites, whereas 68Ga-PSMA-11 PET/CT identified metastatic thyroid disease and demonstrated intensely 68Ga-PSMA-11–expressing distant metastatic lesions. 68Ga-PSMA-11 PET/CT may be considered a potentially useful imaging technique in RCC to detect metastasis and to guide the choice of specific treatments, such as PSMA-based radionuclide therapy in patients with recurrent metastatic RCC.
- oncology
- 177Lu-PSMA-617 therapy
- 18F-FDG PET/CT
- 68Ga-PSMA-11 PET/CT
- clear cell carcinoma
- renal cell carcinoma
Footnotes
Published online Aug. 30, 2022.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user